Skip to main content Skip to navigation
We care about your privacy. Read about your rights and how we protect your data. Get Details

Education & Training

  • Fellowship, 1981
    Memorial Sloan-Kettering Cancer Center
  • Fellowship, Pediatric Neurology, 1981
    Children's Hospital of Philadelphia
  • Fellowship, Neurology, 1981
    Children's Hospital of Philadelphia
  • Residency, Pediatrics, 1978
    Cincinnati Children's Hospital Medical Center
  • MD, 1976
    Northwestern University Feinberg School of Medicine
  • BS, 1972
    Northwestern University

Board Certifications

  • American Board of Pediatrics
  • American Board of Psychiatry & Neurology-Child Neurology

Awards & Recognition

  • Top Doctors Washingtonian (2019)
  • Top Doctors No Va Magazine (2023)

National Provider ID: 1821175167


Roger J. Packer, M.D., is the Gilbert Distinguished Professor of Neurofibromatosis, and is director of both the Gilbert Neurofibromatosis Institute and the Brain Tumor Institute of Children’s National Hospital. Dr. Packer’s present academic titles include professor of Neurology and Pediatrics at George Washington University and clinical professor of Neurosurgery at the University of Virginia in Charlottesville, Virginia. He holds the Gilbert Family Distinguished Professorship in Neurofibromatosis. Prior to coming to Children’s National, Dr. Packer was director of the Brain Tumor Program and professor of Neurology and Pediatrics at the Children’s Hospital of Philadelphia, University of Pennsylvania.

Throughout his career, Dr. Packer has been heavily involved in clinical and applied basic science research. His clinical research has touched on various aspects of adult and child neurology and neuro-oncology, including adult and pediatric brain tumors, neurofibromatosis type 1, the neurologic aspects of childhood neurogenetic diseases, and multiple other topics in general child neurology. Much of his research has focused on the development and performance of clinical trials for adults and children with neurologic, neuro-oncologic and neurogenetic disorders, and he has received peer-reviewed grant support for this research. Many of the clinical trials in neurofibromatosis and brain tumors are translational, bringing advances from the bench to the bedside expeditiously.

Presently, Dr. Packer is principal investigator (PI) at Children’s National for the Pediatric Brain Tumor Consortium (PBTC), formed under the auspices of the National Cancer Institute (NCI); chair of the PBTC Low-Grade Glioma Committee; site PI for Children's National for the Neurofibromatosis Clinical Trials Consortium; and chair of the Medulloblastoma Committee of the Children’s Oncology Group. He has worked closely with the NCI and the National Institute of Neurological Disorders and Stroke (NINDS), and has served on multiple committees setting the directions for neurologic clinical and basic science research for the future. He headed the efforts in pediatrics for the program review, held by the NCI and NINDS for brain tumors. He is presently co-chair of the Brain Malignancy Committee of the NCI. Much of Dr. Packer’s clinical research has been translational in nature. He has been part of studies evaluating the molecular genetics of childhood and adult neurologic diseases and also has coordinated the first gene therapy study for children with malignant brain tumors in the U.S. The majority of the studies now being coordinated by Dr. Packer are studies evaluating innovative agents aimed at the molecular underpinnings of neurologic disease. He has published over 400 original articles and 350 reviews and chapters.

In 2020 the International Symposium on Pediatric Neuro-Oncology bestowed its Lifetime Achievement Award on Dr. Packer for his substantial contributions to pediatric oncology and scientific achievements.

This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

Outside Interests

  • DSMB Roche Pharmaceutical

Research & Publications

Biologic background of pediatric medulloblastoma and ependymoma A review from a translational research standpoint

(2008) Neuro-Oncology

Central nervous system germ cell tumors of childhood presentation and delay in diagnosis

(2007) Neurology

Long term outcome among adult survivors of childhood central nervous system malignancies A report from the Childhood Cancer Survivor Study

(2009) Journal of the National Cancer Institute

Long term outcome among adult survivors of childhood central nervous system malignancies A report from the Childhood Cancer Survivor Study

(2009) Journal of the National Cancer Institute

Massachusetts General Hospital Neurology Grand Rounds

(2011) Improved Outcome for Children with Medulloblastoma in the Molecular Era

Medulloblastoma in childhood new biologic advances

(2007) Lancet Neurology

Minneapolis Childrens Hospital Pediatric Grand Rounds

(2011) Molecular Insights of Medulloblastoma: Towards More Effective Therapy

Objective response of multiply recurrent low grade gliomas to bevacizumab and irinotecan

(2009) Pediatric Blood and Cancer

Phase I study of concurrent RMP7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas

(2005) Cancer

Phase I trial of pirfenidone in children with neurofibromatosis type 1 and plexiform neurofibromas

(2007) Journal of Pediatric Neurology

Phase III prospective randomized study of craniospinal radiation therapy followed by one of two adjuvant chemotherapy regimens for newly diagnosed average risk medulloblastoma

(2006) Journal of Clinical Oncology